GSK and Valeant in $820 million retigabine development deal
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Valeant Pharmaceuticals are to develop a new anti-epilepsy drug, retigabine, in a deal worth up to $820 million. The late-stage investigational drug is a first-in-class neuronal potassium channel opener for adult epilepsy patients with refractory partial onset seizures.